279.69
-12.03
(-4.12%)
At close: April 8 at 4:00:00 PM EDT
280.00
+0.31
+(0.11%)
Pre-Market: 6:39:18 AM EDT
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 11 | 11 | 14 | 13 |
| Avg. Estimate | 6.29 | 6.79 | 27.13 | 27.93 |
| Low Estimate | 5.35 | 5.83 | 23.5 | 22.27 |
| High Estimate | 7.07 | 7.39 | 29.43 | 31.33 |
| Year Ago EPS | 6.17 | 5.85 | 24.64 | 27.13 |
Revenue Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 10 | 10 | 14 | 13 |
| Avg. Estimate | 726.53M | 776.37M | 3.15B | 3.35B |
| Low Estimate | 699.45M | 733.1M | 2.91B | 2.94B |
| High Estimate | 750.7M | 807.5M | 3.3B | 3.56B |
| Year Ago Sales | 677.7M | 714.9M | 2.88B | 3.15B |
| Sales Growth (year/est) | 7.21% | 8.60% | 9.31% | 6.51% |
Earnings History
| Currency in USD | 3/31/2024 | 6/30/2024 | 9/30/2024 | 12/31/2024 |
|---|---|---|---|---|
| EPS Est. | 5.66 | 6.4 | 6.42 | 6.27 |
| EPS Actual | 6.17 | 5.85 | 6.39 | 6.19 |
| Difference | 0.51 | -0.55 | -0.03 | -0.08 |
| Surprise % | 9.02% | -8.56% | -0.54% | -1.23% |
EPS Trend
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | 6.29 | 6.79 | 27.13 | 27.93 |
| 7 Days Ago | 6.32 | 6.83 | 27.19 | 28.02 |
| 30 Days Ago | 6.76 | 7.23 | 27.27 | 28.22 |
| 60 Days Ago | 6.93 | 7.41 | 27.74 | 29.22 |
| 90 Days Ago | 7.09 | 7.59 | 28.12 | 29.19 |
EPS Revisions
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | 1 |
| Up Last 30 Days | -- | 1 | -- | 4 |
| Down Last 7 Days | 2 | 2 | 2 | 1 |
| Down Last 30 Days | 6 | 5 | 3 | 6 |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| UTHR | 5.82% | 21.74% | 17.85% | 0.65% |
| S&P 500 | 6.55% | 6.50% | 9.70% | 14.29% |
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 2/27/2025 |
| Maintains | UBS: Buy to Buy | 1/8/2025 |
| Maintains | Goldman Sachs: Neutral to Neutral | 11/1/2024 |
| Maintains | Ladenburg Thalmann: Buy to Buy | 10/31/2024 |
| Maintains | Oppenheimer: Outperform to Outperform | 10/31/2024 |
| Maintains | Argus Research: Buy to Buy | 10/31/2024 |
Related Tickers
LQDA Liquidia Corporation
11.99
-3.54%
BMRN BioMarin Pharmaceutical Inc.
55.89
-5.53%
MNKD MannKind Corporation
4.6200
-1.49%
INSM Insmed Incorporated
64.97
-4.58%
EXEL Exelixis, Inc.
34.13
-2.04%
NBIX Neurocrine Biosciences, Inc.
87.54
-6.12%
ALNY Alnylam Pharmaceuticals, Inc.
224.32
-3.70%
HALO Halozyme Therapeutics, Inc.
57.54
-3.05%
ARGX argenx SE
548.93
-0.19%
REGN Regeneron Pharmaceuticals, Inc.
556.81
-2.79%